胃底腺型胃癌(gastric adenocarcinoma of fundic gland,GA-FG)是一种罕见的病变,于2010年日本顺天堂大学Uyema教授首次报道该病。它来源于非萎缩正常的胃底腺深部,属于胃癌的一种[1]。这些病变常表现为黏膜下黏膜肌的破裂,但核异型性...胃底腺型胃癌(gastric adenocarcinoma of fundic gland,GA-FG)是一种罕见的病变,于2010年日本顺天堂大学Uyema教授首次报道该病。它来源于非萎缩正常的胃底腺深部,属于胃癌的一种[1]。这些病变常表现为黏膜下黏膜肌的破裂,但核异型性很轻微,且很少显示淋巴管浸润[2,3]。本研究收集四川大学华西医院病理科2018年病理诊断的胃底腺型胃癌2例,讨论其临床病理学特征、免疫组化、诊断与鉴别诊断,并复习相关文献。展开更多
Patients with non-small cell lung cancer(NSCLC)harboring epidermal growth factor receptor(EGFR)mutations show a notable response to tyrosine kinase inhibitor(TKI)treatment.However,almost all patients eventually develo...Patients with non-small cell lung cancer(NSCLC)harboring epidermal growth factor receptor(EGFR)mutations show a notable response to tyrosine kinase inhibitor(TKI)treatment.However,almost all patients eventually develop resistance[1].Given the limited post-resistance treatment options,identifying effective solutions for this sizable group has become a pressing clinical concern.The emergence of immunotherapy has marked a significant breakthrough for patients with NSCLC without driver gene mutations.However,its efficacy remains a subject of debate on the carriers of EGFR mutation.While preclinical studies have hinted at the potential benefits of immunotherapy for patients with EGFR mutations,early clinical investigations have painted a less optimistic picture[2,3].展开更多
文摘胃底腺型胃癌(gastric adenocarcinoma of fundic gland,GA-FG)是一种罕见的病变,于2010年日本顺天堂大学Uyema教授首次报道该病。它来源于非萎缩正常的胃底腺深部,属于胃癌的一种[1]。这些病变常表现为黏膜下黏膜肌的破裂,但核异型性很轻微,且很少显示淋巴管浸润[2,3]。本研究收集四川大学华西医院病理科2018年病理诊断的胃底腺型胃癌2例,讨论其临床病理学特征、免疫组化、诊断与鉴别诊断,并复习相关文献。
基金supported by the China Postdoctoral Science Foundation(2023M742119)the National Natural Science Foundation of China(82403395,82373319,and 82102766)+2 种基金the Natural Science Foundation of Shandong Province(ZR2024QH219)the National Key Clinical Program on Oncologythe Shanghai Science and Technology Innovation Action Plan Medical Innovation Research Special Project(23Y11908600)。
文摘Patients with non-small cell lung cancer(NSCLC)harboring epidermal growth factor receptor(EGFR)mutations show a notable response to tyrosine kinase inhibitor(TKI)treatment.However,almost all patients eventually develop resistance[1].Given the limited post-resistance treatment options,identifying effective solutions for this sizable group has become a pressing clinical concern.The emergence of immunotherapy has marked a significant breakthrough for patients with NSCLC without driver gene mutations.However,its efficacy remains a subject of debate on the carriers of EGFR mutation.While preclinical studies have hinted at the potential benefits of immunotherapy for patients with EGFR mutations,early clinical investigations have painted a less optimistic picture[2,3].
